Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo
AUTOR(ES)
Lev, Avital
FONTE
National Academy of Sciences
RESUMO
A cancer immunotherapy strategy is described herein that combines the advantage of the well established tumor targeting capabilities of high-affinity recombinant fragments of Abs with the known efficient, specific, and potent killing ability of CD8 T lymphocytes directed against highly antigenic MHC-peptide complexes. Structurally, it consists of a previously uncharacterized class of recombinant chimerical molecules created by the genetic fusion of single-chain (sc) Fv Ab fragments, specific for tumor cell surface antigens, to monomeric scHLA-A2 complexes containing immunodominant tumor- or viral-specific peptides. The fusion protein can induce very efficiently tumor cell lysis, regardless of the expression of self peptide-MHC complexes. Moreover, these molecules exhibited very potent antitumor activity in vivo in nude mice bearing preestablished human tumor xenografts. These in vitro and in vivo results suggest that recombinant scFv-MHC-peptide fusion molecules could represent an approach to immunotherapy, bridging Ab and T lymphocyte attack on cancer cells.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=428471Documentos Relacionados
- Catalysis of peptide dissociation from class II MHC-peptide complexes
- A geometric and algebraic view of MHC-peptide complexes and their binding properties
- Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide
- Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo
- Tumor-specific cell-mediated immunity in household contacts of cancer patients..